ALX Oncology Holdings Inc. (ALXO)
Largest Insider Buys in Sector
ALXO Stock Price History Chart
ALXO Stock Performance
About ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.
Insider Activity of ALX Oncology Holdings Inc.
Over the last 12 months, insiders at ALX Oncology Holdings Inc. have bought $198,514 and sold $2.12M worth of ALX Oncology Holdings Inc. stock.
On average, over the past 5 years, insiders at ALX Oncology Holdings Inc. have bought $52.18M and sold $11.34M worth of stock each year.
Highest buying activity among insiders over the last 12 months: GARCIA PETER S (Chief Financial Officer) — $307,015. Lettmann Jason (CHIEF EXECUTIVE OFFICER) — $49,771. Hemrajani Rekha (director) — $46,404.
The last purchase of 30,000 shares for transaction amount of $46,404 was made by Hemrajani Rekha (director) on 2024‑12‑02.
List of Insider Buy and Sell Transactions, ALX Oncology Holdings Inc.
| 2024-12-02 | director | 30,000 0.0532% | $1.55 | $46,404 | -4.22% | |||
| 2024-08-14 | Sale | PRESIDENT & CSO | 1,937 0.0038% | $2.58 | $4,997 | 0.00% | ||
| 2024-08-14 | Sale | CHIEF MEDICAL OFFICER | 1,365 0.0027% | $2.58 | $3,522 | 0.00% | ||
| 2024-08-14 | Sale | SVP, FINANCE AND CAO | 564 0.0011% | $2.58 | $1,455 | 0.00% | ||
| 2024-07-11 | Sale | PRESIDENT & CSO | 20,000 0.0516% | $7.90 | $158,076 | 0.00% | ||
| 2024-07-05 | Sale | SVP, FINANCE AND CAO | 1,823 0.0033% | $5.50 | $10,025 | 0.00% | ||
| 2024-07-01 | Sale | PRESIDENT & CSO | 10,758 0.0204% | $5.82 | $62,599 | 0.00% | ||
| 2024-07-01 | Sale | CHIEF MEDICAL OFFICER | 3,273 0.0062% | $5.82 | $19,045 | 0.00% | ||
| 2024-07-01 | Sale | SVP, FINANCE AND CAO | 1,373 0.0026% | $5.82 | $7,989 | 0.00% | ||
| 2024-06-13 | CHIEF FINANCIAL OFFICER | 12,000 0.0229% | $8.53 | $102,338 | -75.59% | |||
| 2024-06-04 | Sale | PRESIDENT & CSO | 20,000 0.0387% | $8.43 | $168,652 | -74.43% | ||
| 2024-05-13 | Sale | CHIEF MEDICAL OFFICER | 12,000 0.0243% | $15.94 | $191,339 | -85.29% | ||
| 2024-05-06 | Sale | PRESIDENT & CSO | 20,000 0.0399% | $15.92 | $318,334 | -85.20% | ||
| 2024-04-16 | Sale | PRESIDENT & CSO | 50,000 0.0977% | $14.20 | $710,195 | -82.26% | ||
| 2024-04-04 | Sale | PRESIDENT & CSO | 20,000 0.0396% | $11.15 | $223,036 | -76.16% | ||
| 2024-03-14 | CHIEF EXECUTIVE OFFICER | 4,400 0.0085% | $11.31 | $49,771 | -45.56% | |||
| 2024-01-04 | Sale | SVP, Finance and CAO | 2,717 0.0057% | $13.60 | $36,957 | -18.68% | ||
| 2023-12-29 | Sale | President & CSO | 7,179 0.0144% | $15.04 | $107,972 | -27.66% | ||
| 2023-12-29 | Sale | Chief Medical Officer | 3,128 0.0063% | $15.04 | $47,045 | -27.66% | ||
| 2023-12-29 | Sale | Chief Financial Officer | 1,893 0.0038% | $15.04 | $28,471 | -27.66% |
Insider Historical Profitability
| Pons Jaume | PRESIDENT & CSO | 591510 1.1215% | $1.72 | 0 | 18 | |
| Randolph Sophia | CHIEF MEDICAL OFFICER | 325711 0.6175% | $1.72 | 0 | 15 | |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER | 171620 0.3254% | $1.72 | 2 | 4 | +90.48% |
| GARCIA PETER S | CHIEF FINANCIAL OFFICER | 122348 0.232% | $1.72 | 2 | 8 | +90.48% |
| Pinto Shelly | SVP, FINANCE AND CAO | 91549 0.1736% | $1.72 | 0 | 8 | |
| Hemrajani Rekha | director | 33000 0.0626% | $1.72 | 2 | 0 | +90.48% |
| Adelman Robert J | 5268325 9.9887% | $1.72 | 1 | 0 | +90.48% | |
| Graham G. Walmsley | director | 995000 1.8865% | $1.72 | 2 | 0 | +34.88% |
| GOODMAN COREY S | 850000 1.6116% | $1.72 | 1 | 0 | +90.48% | |
| Vivo Capital IX, LLC | 10 percent owner | 789474 1.4968% | $1.72 | 1 | 0 | +90.48% |
| LSV Associates, LLC | 10 percent owner | 285956 0.5422% | $1.72 | 1 | 4 | +90.48% |
| Pietzke Steffen | VP Fin & Chief Acct Officer | 3000 0.0057% | $1.72 | 1 | 0 | +90.48% |
Institutional Investor Ownership
| venBio | $108.15M | 18.62 | 9.7M | 0% | +$0 | 38.37 | |
| Fidelity Investments | $83.88M | 14.44 | 7.52M | +0.67% | +$557,399.65 | 0.01 | |
| Redmile Group | $48.24M | 8.3 | 4.33M | +18.23% | +$7.44M | 0.49 | |
| Vivo Capital | $47.05M | 8.1 | 4.22M | 0% | +$0 | 4.1 | |
| Cormorant Asset Management Lp | $35.03M | 6.03 | 3.14M | 0% | +$0 | 1.63 | |
| OrbiMed | $30.31M | 5.22 | 2.72M | -12.18% | -$4.2M | 0.23 | |
| BlackRock | $24.77M | 4.26 | 2.22M | -0.6% | -$150,881.80 | <0.01 | |
| The Vanguard Group | $17.47M | 3.01 | 1.57M | +4.26% | +$714,213.19 | <0.0001 | |
| Bioimpact Capital Llc | $14.14M | 2.44 | 1.27M | +0.29% | +$41,388.80 | 2.29 | |
| Citadel Advisors LLC | $13.77M | 2.37 | 1.24M | +0.17% | +$23,504.20 | 0.01 | |
| Geode Capital Management | $6.74M | 1.16 | 604,714 | +3.36% | +$219,460.15 | <0.01 | |
| State Street | $6.18M | 1.06 | 553,867 | +10.44% | +$583,936.65 | <0.0001 | |
| Morgan Stanley | $3.83M | 0.66 | 343,137 | -17.07% | -$787,814.29 | <0.0001 | |
| Northern Trust | $2.73M | 0.47 | 245,212 | +0.56% | +$15,297.80 | <0.0001 | |
| Renaissance Technologies | $2.61M | 0.45 | 234,100 | -13.46% | -$405,826.57 | <0.01 | |
| T. Rowe Price | $2.6M | 0.45 | 232,769 | -57.15% | -$3.46M | <0.0001 | |
| Charles Schwab | $2.34M | 0.4 | 209,759 | +0.77% | +$17,784.25 | <0.01 | |
| Federated Hermes | $2.25M | 0.39 | 201,362 | +2.46% | +$53,809.92 | 0.01 | |
| Adage Capital Partners Gp L L C | $1.78M | 0.31 | 160,000 | 0% | +$0 | <0.01 | |
| Goldman Sachs | $1.75M | 0.3 | 157,002 | +73.02% | +$738,787.72 | <0.0001 | |
| Wellington Management Company | $1.42M | 0.24 | 127,037 | +57.44% | +$516,791.51 | <0.0001 | |
| Marshall Wace | $1.36M | 0.23 | 121,546 | +950.62% | +$1.23M | <0.01 | |
| Squarepoint Ops LLC | $1.19M | 0.2 | 106,356 | New | +$1.19M | <0.01 | |
| Nuveen | $1.18M | 0.2 | 105,894 | 0% | +$0 | <0.0001 | |
| Los Angeles Capital Management LLC | $1.1M | 0.19 | 98,960 | -19.82% | -$272,729.00 | <0.01 | |
| BNY Mellon | $889,402.00 | 0.15 | 79,767 | -7.58% | -$72,909.85 | <0.0001 | |
| Standard Life | $738,253.00 | 0.13 | 66,211 | 0% | +$0 | <0.01 | |
| Two Sigma | $729,823.00 | 0.13 | 65,455 | -0.71% | -$5,195.90 | <0.01 | |
| Millennium Management LLC | $671,119.00 | 0.12 | 60,190 | New | +$671,119.00 | <0.0001 | |
| The Manufacturers Life Insurance Company | $670,327.00 | 0.12 | 60,119 | +25.09% | +$134,469.03 | <0.01 | |
| Hrt Financial Llc | $659,000.00 | 0.11 | 59,186 | New | +$659,000.00 | <0.01 | |
| Jane Street Capital | $660,024.00 | 0.11 | 59,195 | +35.77% | +$173,906.48 | <0.01 | |
| State of Wisconsin Investment Board | $606,181.00 | 0.1 | 54,366 | New | +$606,181.00 | <0.01 | |
| Dimensional Fund Advisors | $561,303.00 | 0.1 | 50,341 | -62.49% | -$935,274.57 | <0.0001 | |
| RhumbLine Advisers | $555,931.00 | 0.1 | 49,860 | +3.54% | +$19,021.63 | <0.01 | |
| Td Asset Management Inc | $546,350.00 | 0.09 | 49,000 | -30.4% | -$238,610.00 | <0.0001 | |
| Bank of America | $525,779.00 | 0.09 | 47,155 | -27.18% | -$196,251.43 | <0.0001 | |
| Swiss National Bank | $492,830.00 | 0.09 | 44,200 | New | +$492,830.00 | <0.0001 | |
| Citigroup | $485,103.00 | 0.08 | 43,507 | +817.29% | +$432,218.55 | <0.0001 | |
| Nan Fung Group | $467,743.00 | 0.08 | 41,950 | 0% | +$0 | 0.51 | |
| JPMorgan Chase | $467,152.00 | 0.08 | 41,897 | -11.95% | -$63,398.96 | <0.0001 | |
| DekaBank | $468,000.00 | 0.08 | 41,000 | 0% | +$0 | <0.01 | |
| AllianceBernstein | $432,509.00 | 0.07 | 38,790 | -3.72% | -$16,725.02 | <0.0001 | |
| Walleye Capital | $426,387.00 | 0.07 | 38,241 | -50.87% | -$441,417.20 | <0.01 | |
| Martingale Asset Management L P | $403,575.00 | 0.07 | 36,195 | -14.04% | -$65,941.22 | 0.01 | |
| Cwm Advisors Llc | $369,689.00 | 0.06 | 33,156 | New | +$369,689.00 | 0.04 | |
| Financial Advisory Group | $350,300.00 | 0.06 | 31,417 | 0% | +$0 | 0.06 | |
| American Century Investments | $330,742.00 | 0.06 | 29,663 | +39.95% | +$94,406.92 | <0.0001 | |
| UBS | $324,175.00 | 0.06 | 29,074 | -6.18% | -$21,341.09 | <0.0001 | |
| Connor Clark & Lunn Investment Management Ltd | $324,287.00 | 0.06 | 29,084 | +118.53% | +$175,891.47 | <0.01 |